A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
for Chronic Obstructive Pulmonary Disease
Drug: Dupilumab
9 locations incl. Birmingham
Sponsor: Sanofi
Sex: All·Age: 40 - 85
Code: NCT07053423·Phase 4·Recruiting